IN2011KN04700A - - Google Patents

Download PDF

Info

Publication number
IN2011KN04700A
IN2011KN04700A IN4700KON2011A IN2011KN04700A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A IN 4700KON2011 A IN4700KON2011 A IN 4700KON2011A IN 2011KN04700 A IN2011KN04700 A IN 2011KN04700A
Authority
IN
India
Prior art keywords
apcs
antigen
assessing
kits
peptides
Prior art date
Application number
Other languages
English (en)
Inventor
Pirouz Mohammad Daftarian
Paolo Serafini
Vance Paul Lemmon
Angel Kaifer
Bonnie Beth Blomberg
Raquibul Chowdhury
Norma Kenyon
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of IN2011KN04700A publication Critical patent/IN2011KN04700A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4700KON2011 2009-05-19 2010-05-19 IN2011KN04700A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17961409P 2009-05-19 2009-05-19
PCT/US2010/035355 WO2010135394A1 (en) 2009-05-19 2010-05-19 Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs

Publications (1)

Publication Number Publication Date
IN2011KN04700A true IN2011KN04700A (ko) 2015-07-10

Family

ID=43126487

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4700KON2011 IN2011KN04700A (ko) 2009-05-19 2010-05-19

Country Status (7)

Country Link
US (3) US20120129199A1 (ko)
EP (2) EP3611270B1 (ko)
CN (2) CN110542754A (ko)
CA (1) CA2762586C (ko)
ES (1) ES2731343T3 (ko)
IN (1) IN2011KN04700A (ko)
WO (1) WO2010135394A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488902B (zh) * 2011-11-24 2014-06-25 清华大学 白蛋白修饰的pamam自组装转基因组合物及其制备方法与应用
EP2833918B1 (en) * 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunostimulatory compositions and methods of use thereof
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
EP2972363B1 (en) * 2013-03-15 2019-10-09 University Of Miami Immune-potentiating drug nanocarriers
US20140287438A1 (en) * 2013-03-15 2014-09-25 South Dakota Board Of Regents Rapid and Inexpensive Assay for Evaluation of Antibody Efficacy with Custom-Designed Fluorescent Nanoparticles
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
CN110201192B (zh) * 2019-06-05 2021-08-31 东华大学 一种树状大分子包裹纳米金颗粒探针及其制备和应用
CN111172195A (zh) * 2020-02-13 2020-05-19 翁炳焕 一种新冠肺炎基因治疗制品的制备方法
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409258A1 (fr) 1977-11-21 1979-06-15 Rhone Poulenc Ind Nouvelles compositions a base d'aminoalcoxyamines
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
US6962790B1 (en) * 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
US7807377B2 (en) * 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AU7404800A (en) 1999-09-30 2001-04-30 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
US6632435B1 (en) * 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP2192407A3 (en) * 2001-09-18 2011-04-27 Green Peptide Co., Ltd. Method of detecting cellular immunity and application thereof to drugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
CN1809379A (zh) * 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
JP3101496U (ja) * 2003-07-23 2004-06-10 鴻海精密工業股▲ふん▼有限公司 コネクタ用取り外しツール
WO2006015373A2 (en) * 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
CN101506266A (zh) * 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101711360A (zh) * 2007-03-16 2010-05-19 赛乐思迪斯有限公司 细胞介导的免疫应答检验及其试剂盒
JP5661735B2 (ja) * 2009-04-01 2015-01-28 ユニバーシティ オブ マイアミ ワクチン組成物及びその使用方法

Also Published As

Publication number Publication date
EP3611270B1 (en) 2021-12-01
US20190170742A1 (en) 2019-06-06
EP2432893A1 (en) 2012-03-28
CN102459629B (zh) 2019-08-27
CA2762586A1 (en) 2010-11-25
US20120129199A1 (en) 2012-05-24
EP2432893A4 (en) 2013-06-19
ES2731343T3 (es) 2019-11-15
CN102459629A (zh) 2012-05-16
WO2010135394A1 (en) 2010-11-25
US20170146526A1 (en) 2017-05-25
EP3611270A1 (en) 2020-02-19
CN110542754A (zh) 2019-12-06
EP2432893B1 (en) 2019-05-01
CA2762586C (en) 2018-06-19

Similar Documents

Publication Publication Date Title
IN2011KN04700A (ko)
Reed et al. Key roles of adjuvants in modern vaccines
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
WO2010115046A3 (en) Vaccine compositions and methods of use thereof
Mastelic et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
Thueng-in et al. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines
Cho et al. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma
Fratzke et al. Subunit vaccines using TLR triagonist combination adjuvants provide protection against Coxiella burnetii while minimizing reactogenic responses
Iwama et al. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice
JP2014502961A5 (ko)
WO2022013609A1 (en) Sars-cov-2 vaccine compositions and methods of preparation and use
JP2023520562A (ja) コロナウイルスワクチン
McElhaney Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response
Moyle Progress in Vaccine Development: Vaccines
Kuwentrai et al. Induction of humoral and cellular immunity by intradermal delivery of SARS-CoV-2 nucleocapsid protein using dissolvable microneedles
AU2007291887B2 (en) Method of eliciting or inducing an immune response
Chang et al. A novel vaccine adjuvant for recombinant flu antigens
Jan et al. Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge
Sun et al. Conjugation reaction with 8-arm PEG markedly improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10. 4 fusion protein
Buaklin et al. Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein
Zimmerman et al. Lessons from next generation influenza vaccines for inflammatory disease therapies
Sin MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model
US20220023412A1 (en) Compositions Useful in Both Homologous And Heterologous Vaccine Regimens